StreetInsider.com News Articles

Ardelyx presents real-world Xphozah phosphate data at ASN 2026

Fri, 23 Oct 2026 16:04:27 -0400

Ardelyx, Inc. (Nasdaq: ARDX) presented real-world data at the American Society of Nephrology Kidney Week 2026 showing serum phosphate reductions in adults on dialysis who initiated tenapanor, sold as Xphozah, with or without a phosphate binder.

The analysis included more than 1,400 adults on dialysis with hyperphosphatemia. Across all treatment groups, serum phosphate levels declined over six months of follow-up, with adjusted mean reductions at month six ranging from 0.80 to 1.55 mg/dL. The adjusted probability of reaching a serum phosphate level below 5.5 mg/dL ranged from 16% to 41% across groups. Between 60% and 70% of patients remained on tenapanor

Ardelyx presents real-world Xphozah phosphate data at ASN 2026

Fri, 23 Oct 2026 16:04:27 -0400

Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders

Fri, 23 Oct 2026 16:01:00 -0400

Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated

Additional data highlighted the challenges of managing hyperphosphatemia and the morbidity and mortality risks associated with long-term elevated phosphorus

WALTHAM, Mass., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from a real-world analysis presented at the American Society of Nephrology (ASN) Kidney Week 2026 evaluating real-world serum phosphate outcomes among adults on dialysis who initiated XPHOZAH

Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders

Fri, 23 Oct 2026 16:01:00 -0400

Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated

Additional data highlighted the challenges of managing hyperphosphatemia and the morbidity and mortality risks associated with long-term elevated phosphorus

Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026

Tue, 20 Oct 2026 07:30:00 -0400

Conference call scheduled for 4:30 p.m. Eastern Time

WALTHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Tuesday, November 3, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the third quarter of 2026.

Webcast Information
A live webcast of the conference call and accompanying slides will be available in the “Events and

Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026

Tue, 20 Oct 2026 07:30:00 -0400

Conference call scheduled for 4:30 p.m. Eastern Time

Webcast Information
A live webcast of the conference call and accompanying slides will be available in the “Events and

Ardelyx data shows fewer doctor visits after IBS-C drug initiation

Mon, 12 Oct 2026 08:02:46 -0400

Ardelyx, Inc. (Nasdaq: ARDX) presented real-world data at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting showing a reduction in gastrointestinal-related healthcare resource utilization among adults with irritable bowel syndrome with constipation (IBS-C) following initiation of its drug IBSRELA® (tenapanor).

The data came from a retrospective, observational analysis of 470 patients with IBS-C treated at a national gastroenterology practice. Median GI-related healthcare visits dropped from 4.5 in the year before tenapanor initiation to 3.0 in the year after (P<0.001). Reductions were also observed in subgroup analyses among patients who had previously tried at least one IBS-C medication, regardless of

Ardelyx data shows fewer doctor visits after IBS-C drug initiation

Mon, 12 Oct 2026 08:02:46 -0400

Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

Mon, 12 Oct 2026 08:01:00 -0400

Additional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of life

WALTHAM, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from a real-world analysis being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting showing that gastrointestinal-related healthcare resource utilization (GI-HCRU) dropped significantly after adults with irritable bowel syndrome with constipation (IBS-C) started IBSRELA®

Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

Mon, 12 Oct 2026 08:01:00 -0400

Additional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of life

Ardelyx to present three posters at ASN Kidney Week 2026

Mon, 05 Oct 2026 08:01:23 -0400

Ardelyx, Inc. (Nasdaq: ARDX) announced it will present three poster abstracts at the American Society of Nephrology Kidney Week 2026, scheduled for October 21–25 in Denver, Colorado.

All three presentations are set for October 23, from 10:00 a.m. to 12:00 p.m. MDT. The posters will cover real-world effectiveness of tenapanor used alongside different phosphate binders, patient perspectives on managing hyperphosphatemia in an end-stage kidney disease cohort, and an analysis of morbidity and mortality risks linked to cumulative hyperphosphatemia in U.S. dialysis patients.

Ardelyx will also host an Exhibitor Spotlight session on October 23 at 11:00 a.m. MDT, during which nephrologist Samuel A.

Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026

Mon, 05 Oct 2026 08:01:00 -0400

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced three abstracts will be presented at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 21–25, 2026 in Denver, Colorado.

The poster presentations will highlight new research pertaining to the hyperphosphatemia treatment landscape, including real-world evidence evaluating the effectiveness of tenapanor with different phosphate binders, patient perspectives on the challenges of managing hyperphosphatemia, and an analysis of the impact long-term

Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026

Mon, 05 Oct 2026 08:01:00 -0400

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Ardelyx, Inc. (ARDX)

Thu, 01 Oct 2026 07:25:00 -0400

Philadelphia, Pennsylvania--(Newsfile Corp. - October 1, 2026) - What is The Investigation About? Grabar Law Office is investigating whether certain officers and directors of Ardelyx, Inc. (NYSE: ARDX) breached their fiduciary duties owed to the Company and its shareholders.

If you have held Ardelyx, Inc. (NYSE: ARDX) shares since on or before January 13, 2025, visit https://grabarlaw.com/the-latest/ardx-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. Alternatively, investors who purchased or

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Ardelyx, Inc. (ARDX)

Thu, 01 Oct 2026 07:25:00 -0400

Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards

Wed, 30 Sep 2026 08:01:00 -0400

Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the Year

WALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that it received multiple honors at the 2026 PM360 Trailblazer Awards, recognizing the company, its leadership, and the work of teams across the organization.

Ardelyx received the following awards:

Life Sciences Manufacturer CEO of the Year: Mike Raab
Podcast Initiative Gold Winner: Gut Matters: Discoveries

Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards

Wed, 30 Sep 2026 08:01:00 -0400

Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the Year

Ardelyx received the following awards:

Life Sciences Manufacturer CEO of the Year: Mike Raab
Podcast Initiative Gold Winner: Gut Matters: Discoveries

Ardelyx to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 07:30:00 -0400

WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences:

Citi's 2026 Biopharma Back to School Conference
Location: New York, NY
Investor Meetings: Wednesday, September 9

2026 Cantor Global Healthcare Conference
Location: New York, NY
Fireside Chat: Thursday, September 10 at 11:30 AM ET
Investor Meetings: Thursday, September 10

Morgan Stanley 24th Annual Global Healthcare Conference
Location: New York, NY
Fireside

Ardelyx to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 07:30:00 -0400

Citi's 2026 Biopharma Back to School Conference
Location: New York, NY
Investor Meetings: Wednesday, September 9

2026 Cantor Global Healthcare Conference
Location: New York, NY
Fireside Chat: Thursday, September 10 at 11:30 AM ET
Investor Meetings: Thursday, September 10

Morgan Stanley 24th Annual Global Healthcare Conference
Location: New York, NY
Fireside

Form 4 ARDELYX, INC. For: Aug 21 Filed by: Hohenleitner Susan

Tue, 25 Aug 2026 19:19:00 -0400

si-local-file:///var/storage/secattach/20260825/26976037.html

Form 4 ARDELYX, INC. For: Aug 21 Filed by: Hohenleitner Susan

Tue, 25 Aug 2026 19:19:00 -0400

si-local-file:///var/storage/secattach/20260825/26976037.html

Form 4 ARDELYX, INC. For: Aug 21 Filed by: Reilly Joseph James

Tue, 25 Aug 2026 19:18:00 -0400

si-local-file:///var/storage/secattach/20260825/26976036.html

Form 4 ARDELYX, INC. For: Aug 21 Filed by: Reilly Joseph James

Tue, 25 Aug 2026 19:18:00 -0400

si-local-file:///var/storage/secattach/20260825/26976036.html

Form 4 ARDELYX, INC. For: Aug 21 Filed by: Bishop John E

Tue, 25 Aug 2026 19:17:00 -0400

si-local-file:///var/storage/secattach/20260825/26976035.html

Form 4 ARDELYX, INC. For: Aug 21 Filed by: Bishop John E

Tue, 25 Aug 2026 19:17:00 -0400

si-local-file:///var/storage/secattach/20260825/26976035.html